AbCellera Biologics Financial Ratios
NASDAQ: ABCLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
12.55+0.525 (+4.37%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
AbCellera Biologics ratio analysis
AbCellera Biologics earned a net margin of -194.9% in FY 2025, up from -564.8% a year earlier. Return on equity reached -15.1%, meaning AbCellera Biologics generated -0.15 dollars of profit for every dollar of shareholders' equity. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
AbCellera Biologics financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | — | — | — | 20.26 | 29.79 | 89.42 | — |
| Price / sales | 13.64 | 31.95 | 43.42 | 5.95 | 10.51 | 27.48 | — |
| Price / book | 1.06 | 0.87 | 1.43 | 2.34 | 3.84 | 7.71 | — |
| Operating margin | -289.0% | -1,091.7% | -623.8% | 44.6% | 54.5% | 66.9% | -35.5% |
| Net margin | -194.9% | -564.8% | -385.0% | 32.7% | 40.9% | 51.0% | -19.0% |
| Free cash flow margin | -231.7% | -648.4% | -317.7% | 42.6% | 49.6% | 5.6% | -11.2% |
| Return on equity (ROE) | -15.1% | -15.4% | -12.7% | 12.9% | 15.0% | 14.3% | -21.6% |
| Return on assets (ROA) | -10.8% | -12.0% | -9.8% | 10.3% | 11.6% | 11.8% | — |
| Debt / equity | — | — | — | — | — | 0.00 | — |
| Current ratio | 11.32 | 9.81 | 7.33 | 8.67 | 7.70 | 7.86 | — |
| Revenue growth | 160.6% | -24.2% | -92.2% | 29.4% | 60.9% | 1,907.9% | — |
| EPS growth | — | — | -202.0% | 4.2% | 6.7% | — | — |